Zydus Cadila launches 'Ujvira' to treat breast cancer - The Hindu BusinessLine

Zydus Cadila launches ‘Ujvira’ to treat breast cancer
May 24, 2021
Treatment cost to come down by 80% for the patients
In a breakthrough in breast cancer treatment, pharma major Zydus Cadila (Cadila Healthcare Limited) on Monday announced the launch of Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) biosimilar, which is considered a highly effective drug for treating both early and advanced HER2-positive breast cancer. The company launched the product under the brand name ‘Ujvira’.
The human epidermal growth factor receptor 2 (HER2)-positive breast cancer is considered an aggressive form and constitutes 20 to 25% of all breast cancers, the company informed, adding that its new product can reduce the treatment cost by almost 80 per cent.

Related Keywords

India ,Trastuzumab Emtansine ,Sharvil Patel ,Zydus Cadila Healthcare Limited On ,Cadila Healthcare ,Zydus Cadila ,Cadila Healthcare Limited ,Antibody Drug Conjugate ,Managing Director ,Antibody Drug ,Ujvira ,Breast Cancer ,Reduced Treatment Cost ,இந்தியா ,ஷார்வில் படேல் ,காடிலா சுகாதாரம் ,ஜய்துச் காடிலா ,காடிலா சுகாதாரம் வரையறுக்கப்பட்டவை ,நிர்வகித்தல் இயக்குனர் ,ஆன்டிபாடி மருந்து ,மார்பக புற்றுநோய் ,